Sandro S Santagata

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5998326/publications.pdf

Version: 2024-02-01

219 papers	20,365 citations	11639 70 h-index	12585 132 g-index
245 all docs	245 docs citations	245 times ranked	24011 citing authors

#	Article	IF	Citations
1	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro-Oncology, 2022, 24, 101-113.	0.6	38
2	Multimodal platform for assessing drug distribution and response in clinical trials. Neuro-Oncology, 2022, 24, 64-77.	0.6	4
3	A molecularly integrated grade for meningioma. Neuro-Oncology, 2022, 24, 796-808.	0.6	83
4	Scope2Screen: Focus+Context Techniques for Pathology Tumor Assessment in Multivariate Image Data. IEEE Transactions on Visualization and Computer Graphics, 2022, 28, 259-269.	2.9	9
5	Narrative online guides for the interpretation of digital-pathology images and tissue-atlas data. Nature Biomedical Engineering, 2022, 6, 515-526.	11.6	17
6	MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging. Nature Methods, 2022, 19, 311-315.	9.0	102
7	Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer. Nature Communications, 2022, 13, 835.	5.8	32
8	Molecular and Clinical Characterization of Radiation-Induced Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.4	0
9	Abstract P2-07-13: High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer. Cancer Research, 2022, 82, P2-07-13-P2-07-13.	0.4	0
10	HSF2 cooperates with HSF1 to drive a transcriptional program critical for the malignant state. Science Advances, 2022, 8, eabj6526.	4.7	13
11	MITI minimum information guidelines for highly multiplexed tissue images. Nature Methods, 2022, 19, 262-267.	9.0	37
12	Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 2022, 375, 1254-1261.	6.0	1,539
13	Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology, 2022, 24, 316-326.	4.6	34
14	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nature Communications, 2022, 13, 1325.	5.8	31
15	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro-Oncology, 2022, 24, 1140-1149.	0.6	13
16	The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Cancer Discovery, 2022, 12, 1518-1541.	7.7	87
17	A human breast atlas integrating single-cell proteomics and transcriptomics. Developmental Cell, 2022, 57, 1400-1420.e7.	3.1	50
18	DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations. Neuro-Oncology, 2022, 24, i28-i28.	0.6	1

#	Article	IF	Citations
19	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nature Cancer, 2021, 2, 66-82.	5.7	126
20	Sporadic multiple meningiomas harbor distinct driver mutations. Acta Neuropathologica Communications, 2021, 9, 8.	2.4	12
21	HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2021, 27, 1706-1719.	3.2	14
22	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibodyâ€“Drug Conjugate. Cancer Discovery, 2021, 11, 1508-1523.	7.7	20
23	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. Nature Cancer, 2021, 2, 498-502.	5.7	26
24	Prognostication for meningiomas: H3K27me3 to the rescue?. Neuro-Oncology, 2021, 23, 1218-1219.	0.6	1
25	Temporal and spatial topography of cell proliferation in cancer.. Journal of Clinical Oncology, 2021, 39, 3122-3122.	0.8	0
26	Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.. Journal of Clinical Oncology, 2021, 39, 2000-2000.	0.8	18
27	Skull Base Tumors: Neuropathology and Clinical implications. Neurosurgery, 2021, 90, .	0.6	3
28	Abstract 122: Highly multiplexed, spatially-resolved tissue imaging of genetically engineered mouse models of cancer to discover and characterize immune regulators of tumorigenesis. , 2021, , .		0
29	Abstract 4: Temporal and spatial topography of cell proliferation in cancer. , 2021, , .		1
30	Abstract 1816: Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma. , 2021, , .		0
31	P04.09 Frequent inactivating mutations of PBRM1 in meningioma with papillary features. Neuro-Oncology, 2021, 23, ii20-ii20.	0.6	0
32	Antigen dominance hierarchies shape TCF1+ progenitor CD8 TÂcell phenotypes in tumors. Cell, 2021, 184, 4996-5014.e26.	13.5	84
33	Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery. Npj Breast Cancer, 2021, 7, 116.	2.3	10
34	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell, 2021, 184, 4753-4771.e27.	13.5	99
35	PATH-37. DISTINCT GENOMIC SUBCLASSES OF HIGH-GRADE/PROGRESSIVE MENINGIOMAS: NF2-ASSOCIATED, NF2-EXCLUSIVE, AND NF2-AGNOSTIC. Neuro-Oncology, 2021, 23, vi123-vi123.	0.6	0
36	CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. Neuro-Oncology, 2021, 23, vi59-vi59.	0.6	4

#	Article	IF	Citations
37	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. Neuro-Oncology, 2021, 23, vi57-vi57.	0.6	0
38	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. Neuro-Oncology, 2021, 23, vi72-vi72.	0.6	0
39	An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathologica, 2020, 139, 643-665.	3.9	102
40	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clinical Breast Cancer, 2020, 20, 145-151.e2.	1.1	21
41	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii9-ii9.	0.4	0
42	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathologica Communications, 2020, 8, 171.	2.4	58
43	SYLARAS: A Platform for the Statistical Analysis and Visual Display of Systemic Immunoprofiling Data and Its Application to Glioblastoma. Cell Systems, 2020, 11, 272-285.e9.	2.9	8
44	Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathologica, 2020, 140, 89-93.	3.9	32
45	Telomere length alterations and ATRX/DAXX loss in pituitary adenomas. Modern Pathology, 2020, 33, 1475-1481.	2.9	13
46	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature Communications, 2020, 11, 1459.	5.8	176
47	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nature Genetics, 2020, 52, 371-377.	9.4	177
48	Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma. Cancer Research, 2020, 80, 1258-1267.	0.4	67
49	Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1. JCO Precision Oncology, 2020, 4, 79-90.	1.5	27
50	A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell, 2020, 37, 705-719.e6.	7.7	35
51	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	13.5	334
52	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	13.7	374
53	HSF1 phase transition mediates stress adaptation and cell fate decisions. Nature Cell Biology, 2020, 22, 151-158.	4.6	67
54	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. Neuro-Oncology, 2020, 22, ii43-ii44.	0.6	3

#	Article	IF	Citations
55	860â€...Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer. , 2020, , .		1
56	Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.. Journal of Clinical Oncology, 2020, 38, 2502-2502.	0.8	17
57	Minerva: a light-weight, narrative image browser for multiplexed tissue images. Journal of Open Source Software, 2020, 5, 2579.	2.0	22
58	Molecular Taxonomy of Meningioma. , 2020, 81, .		0
59	RARE-07. THE LANDSCAPE OF GENOMIC ALTERATIONS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMAS. Neuro-Oncology, 2020, 22, iii443-iii443.	0.6	0
60	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. Neuro-Oncology, 2020, 22, ii44-ii44.	0.6	5
61	PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE. Neuro-Oncology, 2020, 22, ii164-ii164.	0.6	0
62	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii228-ii228.	0.6	0
63	TAMI-45. PHENOGENOMIC CHARACTERIZATION OF IMMUNOMODULATORY PURINERGIC SIGNALING IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii222-ii223.	0.6	0
64	PATH-35. A SCALABLE MOLECULARLY INTEGRATED CLASSIFIER FOR MENINGIOMA OUTPERFORMS WHO CLASSIFICATION. Neuro-Oncology, 2020, 22, ii172-ii172.	0.6	0
65	Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer, 2019, 125, 2910-2914.	2.0	58
66	Rapid MALDI mass spectrometry imaging for surgical pathology. Npj Precision Oncology, 2019, 3, 17.	2.3	59
67	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nature Protocols, 2019, 14, 2900-2930.	5.5	92
68	Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nature Chemical Biology, 2019, 15, 681-689.	3.9	275
69	Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. Clinical Cancer Research, 2019, 25, 6392-6405.	3.2	37
70	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications, 2019, 10, 2400.	5.8	37
71	MEDU-37. NEURONAL DIFFERENTIATION AND CELL-CYCLE PROGRAMS MEDIATE RESPONSE AND RESISTANCE TO BET-BROMODOMAIN INHIBITION IN MYC-DRIVEN MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii111-ii111.	0.6	0
72	DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS. Neuro-Oncology, 2019, 21, vi73-vi73.	0.6	0

#	Article	IF	Citations
73	RARE-04. TARGETED TREATMENT OF PAPILLARY CRANIOPHARYNGIOMAS HARBORING BRAFV600E MUTATIONS. Neuro-Oncology, 2019, 21, vi222-vi222.	0.6	0
74	Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer. Scientific Data, 2019, 6, 323.	2.4	39
75	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. Neuro-Oncology, 2019, 21, vi111-vi111.	0.6	1
76	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. Neuro-Oncology, 2019, 21, vi58-vi59.	0.6	0
77	The impact of histopathology and NAB2â€“STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. Acta Neuropathologica, 2019, 137, 307-319.	3.9	44
78	Molecular characterization and management of secondary resistance to serial TRK inhibitors.. Journal of Clinical Oncology, 2019, 37, e22547-e22547.	0.8	1
79	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro-Oncology, 2018, 20, 1101-1112.	0.6	67
80	Meningioma transcription factors link cell lineage with systemic metabolic cues. Neuro-Oncology, 2018, 20, 1331-1343.	0.6	9
81	Uncovering the links between systemic hormones and oncogenic signaling in the pathogenesis of meningioma. Annals of Oncology, 2018, 29, 537-540.	0.6	4
82	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. JCO Precision Oncology, 2018, 2018, 1-12.	1.5	35
83	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi140-vi141.	0.6	0
84	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 148-157.	1.8	2
85	New molecular targets in meningiomas: the present and the future. Current Opinion in Neurology, 2018, 31, 740-746.	1.8	13
86	MBRS-01. A CASE OF MOLECULARLY PROFILED EXTRANEURAL MEDULLOBLASTOMA METASTASES IN A CHILD. Neuro-Oncology, 2018, 20, i128-i128.	0.6	0
87	Updates in prognostic markers for gliomas. Neuro-Oncology, 2018, 20, vii17-vii26.	0.6	78
88	PATH-16. MOLECULAR PATHOLOGY AND CLINICAL CHARACTERISTICS OF MMR DEFICIENCY (MMRd) IN DIFFUSE GLIOMAS. Neuro-Oncology, 2018, 20, vi161-vi161.	0.6	0
89	RARE-08. GRADING CONSIDERATIONS FOR MENINGEAL SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA. Neuro-Oncology, 2018, 20, vi237-vi238.	0.6	1
90	Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	3.0	164

#	Article	IF	Citations
91	Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. Journal of Neuropathology and Experimental Neurology, 2018, 77, 877-882.	0.9	95
92	Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. ELife, 2018, 7, .	2.8	474
93	A case of molecularly profiled extraneural medulloblastoma metastases in a child. BMC Medical Genetics, 2018, 19, 10.	2.1	3
94	CRAN-11. MULTIPLEXED IMMUNOFLUORESCENCE REVEALS POTENTIAL PD-1/PD-L1 PATHWAY VULNERABILITIES IN CRANIOPHARYNGIOMA. Neuro-Oncology, 2018, 20, i39-i39.	0.6	2
95	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathologica, 2018, 136, 779-792.	3.9	66
96	Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. Journal of Neuro-Oncology, 2018, 140, 269-279.	1.4	45
97	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2003-2003.	0.8	1
98	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro-Oncology, 2017, 19, now235.	0.6	99
99	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro-Oncology, 2017, 19, now294.	0.6	54
100	BAP1 mutations in high-grade meningioma: implications for patient care. Neuro-Oncology, 2017, 19, 1447-1456.	0.6	125
101	Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology, 2017, 158, 2284-2291.	1.4	53
102	Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. Journal of Neurosurgery, 2017, 127, 438-444.	0.9	48
103	Genomic landscape of high-grade meningiomas. Npj Genomic Medicine, 2017, 2, .	1.7	130
104	Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 382-387.	3.3	47
105	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. Npj Precision Oncology, 2017, 1, 5.	2.3	49
106	Nuclear CRX and FOXJ1 Expression Differentiates Nonâ€“Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. American Journal of Surgical Pathology, 2017, 41, 1410-1421.	2.1	11
107	Treatment of brain metastases in the modern genomic era. , 2017, 170, 64-72.		40
108	Landscape of Genomic Alterations in Pituitary Adenomas. Clinical Cancer Research, 2017, 23, 1841-1851.	3.2	94

#	Article	IF	Citations
109	Fatal Eastern Equine Encephalitis in a Patient on Maintenance Rituximab: A Case Report. Open Forum Infectious Diseases, 2017, 4, ofx021.	0.4	18
110	Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. Cell Communication and Signaling, 2017, 15, 34.	2.7	21
111	Rapid Mass Spectrometry Imaging to Assess the Biochemical Profile of Pituitary Tissue for Potential Intraoperative Usage. Advances in Cancer Research, 2017, 134, 257-282.	1.9	6
112	Transcriptomic and Genomic Analyses of Human Craniopharyngioma. , 2017, , 27-39.		3
113	Radiographic Prediction of Meningioma Grade and Genomic Profile. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.4	1
114	Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS ONE, 2017, 12, e0187908.	1.1	109
115	Orbital leiomyosarcoma metastasis presenting prior to diagnosis of the primary tumor. Digital Journal of Ophthalmology: DJO, 2017, 23, 113-117.	0.2	2
116	Craniopharyngioma Pathogenesis and Implications for Medical Management. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.4	0
117	Genomic Landscape of High-grade Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.4	0
118	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget, 2016, 7, 76565-76576.	0.8	100
119	Decreased <scp>FOXJ1</scp> expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. Journal of Pathology, 2016, 238, 584-597.	2.1	29
120	Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy. Neurosurgical Focus, 2016, 41, E2.	1.0	28
121	Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics. Neurosurgical Focus, 2016, 41, E3.	1.0	16
122	Label-Free Neurosurgical Pathology with Stimulated Raman Imaging. Cancer Research, 2016, 76, 3451-3462.	0.4	119
123	ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. European Journal of Endocrinology, 2016, 174, R139-R144.	1.9	61
124	Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes. Modern Pathology, 2016, 29, 1446-1459.	2.9	15
125	Susan Lindquist (1949â€“2016). Science, 2016, 354, 974-974.	6.0	3
126	Checkpoint inhibition in meningiomas. Immunotherapy, 2016, 8, 721-731.	1.0	22

#	Article	IF	Citations
127	Case-Based Review: meningioma. Neuro-Oncology Practice, 2016, 3, 120-134.	1.0	6
128	Genomic landscape of intracranial meningiomas. Journal of Neurosurgery, 2016, 125, 525-535.	0.9	104
129	Successful Treatment of a Progressive BRAF V600Eâ€“Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. Journal of Clinical Oncology, 2016, 34, e87-e89.	0.8	77
130	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	9.4	214
131	Oncogenic PI3K mutations are as common asAKT1andSMOmutations in meningioma. Neuro-Oncology, 2016, 18, 649-655.	0.6	221
132	A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro-Oncology, 2016, 18, 269-274.	0.6	64
133	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Journal of the National Cancer Institute, 2016, 108, djv310.	3.0	182
134	SUâ€Đâ€207Bâ€02: Early Grade Classification in Meningioma Patients Combining Radiomics and Semantics Data. Medical Physics, 2016, 43, 3348-3349.	1.6	3
135	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget, 2015, 6, 4704-4716.	0.8	127
136	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro-Oncology, 2015, 17, 1486-1496.	0.6	39
137	Profiling of adrenocorticotropic hormone and arginine vasopressin in human pituitary gland and tumor thin tissue sections using droplet-based liquid-microjunction surface-sampling-HPLCâ€“ESI-MSâ€“MS. Analytical and Bioanalytical Chemistry, 2015, 407, 5989-5998.	1.9	24
138	MALDI mass spectrometry imaging analysis of pituitary adenomas for near-real-time tumor delineation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9978-9983.	3.3	73
139	Molecular typing of meningiomas by desorption electrospray ionization mass spectrometry imaging for surgical decision-making. International Journal of Mass Spectrometry, 2015, 377, 690-698.	0.7	46
140	ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genetics, 2015, 208, 345-350.	0.2	73
141	Intraoperative Magnetic Resonance Imaging in Intracranial Glioma Resection: A Single-Center, Retrospective Blinded Volumetric Study. World Neurosurgery, 2015, 84, 528-536.	0.7	38
142	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro-Oncology, 2015, 17, 1344-1355.	0.6	40
143	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	7.7	821
144	Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia. Modern Pathology, 2015, 28, 596-606.	2.9	55

#	Article	IF	Citations
145	Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. ELife, 2015, 4, .	2.8	67
146	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget, 2014, 5, 10596-10606.	0.8	65
147	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology, 2014, 16, 567-578.	0.6	140
148	The Master Regulator of the Cellular Stress Response (HSF1) Is Critical for Orthopoxvirus Infection. PLoS Pathogens, 2014, 10, e1003904.	2.1	35
149	HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18297-18302.	3.3	104
150	Artifacts to avoid while taking advantage of topâ€down mass spectrometry based detection of protein Sâ€thiolation. Proteomics, 2014, 14, 1152-1157.	1.3	20
151	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathologica Communications, 2014, 2, 167.	2.4	65
152	Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy. Expert Review of Anticancer Therapy, 2014, 14, 1385-1389.	1.1	17
153	Taxonomy of breast cancer based on normal cell phenotype predicts outcome. Journal of Clinical Investigation, 2014, 124, 859-870.	3.9	164
154	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genetics, 2014, 46, 161-165.	9.4	408
155	The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy. Cell, 2014, 158, 564-578.	13.5	298
156	Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15184-15189.	3.3	207
157	Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11121-11126.	3.3	230
158	Structureâ€“Activity Relationships for Withanolides as Inducers of the Cellular Heat-Shock Response. Journal of Medicinal Chemistry, 2014, 57, 2851-2863.	2.9	63
159	Atypical presentation of cerebral schistosomiasis four years after exposure to Schistosoma mansoni. Epilepsy & Behavior Case Reports, 2014, 2, 80-85.	1.5	19
160	Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro-Oncology, 2014, 16, 1547-1553.	0.6	80
161	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget, 2014, 5, 8083-8092.	0.8	55
162	Integrative whole-genome copy number analysis and mutation profiling of FFPE brain tumor specimens and potential in designing multi-arm clinical trials.. Journal of Clinical Oncology, 2014, 32, 11098-11098.	0.8	0

#	Article	IF	Citations
163	Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. Scientific Reports, 2013, 3, 2859.	1.6	118
164	Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1611-1616.	3.3	251
165	Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nature Biotechnology, 2013, 31, 630-637.	9.4	120
166	Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nature Genetics, 2013, 45, 285-289.	9.4	532
167	Rapid, Label-Free Detection of Brain Tumors with Stimulated Raman Scattering Microscopy. Science Translational Medicine, 2013, 5, 201ra119.	5.8	398
168	Mass spectrometry imaging as a tool for surgical decisionâ€making. Journal of Mass Spectrometry, 2013, 48, 1178-1187.	0.7	85
169	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8188-8193.	3.3	188
170	Tight Coordination of Protein Translation and HSF1 Activation Supports the Anabolic Malignant State. Science, 2013, 341, 1238303.	6.0	234
171	Eastern Equine Encephalitis in Children, Massachusetts and New Hampshire,USA, 1970â€“2010. Emerging Infectious Diseases, 2013, 19, 194-201.	2.0	58
172	Combined whole genome copy number genotyping and multiplex somatic mutation profiling of FFPE brain tumor specimens for clinical diagnosis and trial selection.. Journal of Clinical Oncology, 2013, 31, 2030-2030.	0.8	1
173	Abstract B067: Taxonomy of breast cancer based on normal cell phenotype and ontology. , 2013, , .		0
174	Classifying Human Brain Tumors by Lipid Imaging with Mass Spectrometry. Cancer Research, 2012, 72, 645-654.	0.4	273
175	Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution. Current Molecular Medicine, 2012, 12, 1108-1124.	0.6	62
176	HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers. Cell, 2012, 150, 549-562.	13.5	602
177	Using the Heat-Shock Response To Discover Anticancer Compounds that Target Protein Homeostasis. ACS Chemical Biology, 2012, 7, 340-349.	1.6	129
178	DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues. PLoS ONE, 2012, 7, e38881.	1.1	28
179	Relapsing Tumefactive Lesion in an Adult with Medulloblastoma Previously Treated with Chemoradiotherapy and Stem Cell Transplant. Pathology and Oncology Research, 2012, 18, 539-543.	0.9	1
180	Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. Journal of Clinical Investigation, 2012, 122, 3742-3754.	3.9	118

#	Article	IF	Citations
181	Genomic characterization of meningiomas.. Journal of Clinical Oncology, 2012, 30, 2020-2020.	0.8	0
182	Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas. Journal of Molecular Diagnostics, 2011, 13, 669-677.	1.2	81
183	Desorption Electrospray Ionization then MALDI Mass Spectrometry Imaging of Lipid and Protein Distributions in Single Tissue Sections. Analytical Chemistry, 2011, 83, 8366-8371.	3.2	142
184	Multiplex Amplification Coupled with COLD-PCR and High Resolution Melting Enables Identification of Low-Abundance Mutations in Cancer Samples with Low DNA Content. Journal of Molecular Diagnostics, 2011, 13, 220-232.	1.2	31
185	BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS ONE, 2011, 6, e17948.	1.1	268
186	Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. Journal of Clinical Oncology, 2011, 29, 1424-1430.	0.8	609
187	High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18378-18383.	3.3	275
188	Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17385-17390.	3.3	129
189	Derivation of Pre-X Inactivation Human Embryonic Stem Cells under Physiological Oxygen Concentrations. Cell, 2010, 141, 872-883.	13.5	367
190	Novel MPZ mutations and congenital hypomyelinating neuropathy. Neuromuscular Disorders, 2010, 20, 725-729.	0.3	14
191	CRX Is a Diagnostic Marker of Retinal and Pineal Lineage Tumors. PLoS ONE, 2009, 4, e7932.	1.1	43
192	Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults. Clinical Cancer Research, 2009, 15, 330-337.	3.2	147
193	Rapid selection of cyclic peptides that reduce Î±-synuclein toxicity in yeast and animal models. Nature Chemical Biology, 2009, 5, 655-663.	3.9	130
194	Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS ONE, 2009, 4, e7887.	1.1	316
195	Mycosis Fungoides With Leptomeningeal Involvement. Journal of Clinical Oncology, 2007, 25, 5658-5661.	0.8	4
196	Embryonic Stem Cell Transcription Factor Signatures in the Diagnosis of Primary and Metastatic Germ Cell Tumors. American Journal of Surgical Pathology, 2007, 31, 836-845.	2.1	169
197	Post-irradiation meningioma with sarcoidosis. Journal of Neuro-Oncology, 2007, 82, 271-272.	1.4	3
198	Comparative Analysis of Germ Cell Transcription Factors in CNS Germinoma Reveals Diagnostic Utility of NANOG. American Journal of Surgical Pathology, 2006, 30, 1613-1618.	2.1	49

#	Article	IF	Citations
199	Anaplastic variant of medulloblastoma mimicking a vestibular schwannoma. Journal of Neuro-Oncology, 2006, 81, 49-51.	1.4	4
200	Intramedullary neuroma of the cervicomedullary junction. Journal of Neurosurgery: Spine, 2006, 5, 362-366.	0.9	8
201	A HIF1Î± Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics, 2005, 1, e8.	1.5	394
202	JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence. Cancer Research, 2004, 64, 6854-6857.	0.4	310
203	FokI requires two specific DNA sites for cleavage. Journal of Molecular Biology, 2001, 309, 69-78.	2.0	160
204	G-Protein Signaling Through Tubby Proteins. Science, 2001, 292, 2041-2050.	6.0	352
205	Recombinase activating gene enzymes of lymphocytes. Current Opinion in Hematology, 2001, 8, 41-46.	1.2	12
206	V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood, 2001, 97, 81-88.	0.6	324
207	The genetic and biochemical basis of Omenn syndrome. Immunological Reviews, 2000, 178, 64-74.	2.8	56
208	Mutations in Conserved Regions of the Predicted RAG2 Kelch Repeats Block Initiation of V(D)J Recombination and Result in Primary Immunodeficiencies. Molecular and Cellular Biology, 2000, 20, 5653-5664.	1.1	58
209	N-terminal RAG1 frameshift mutations in Omenn's syndrome: Internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14572-14577.	3.3	65
210	Definition of Minimal Domains of Interaction Within the Recombination-Activating Genes 1 and 2 Recombinase Complex. Journal of Immunology, 2000, 164, 5826-5832.	0.4	43
211	Molecular Cloning and Characterization of a Mouse Homolog of Bacterial ClpX, a Novel Mammalian Class II Member of the Hsp100/Clp Chaperone Family. Journal of Biological Chemistry, 1999, 274, 16311-16319.	1.6	31
212	Omenn syndrome: a disorder of Rag1 and Rag2 genes. Journal of Clinical Immunology, 1999, 19, 87-97.	2.0	73
213	Implication of Tubby Proteins as Transcription Factors by Structure-Based Functional Analysis. Science, 1999, 286, 2119-2125.	6.0	196
214	The RAG1/RAG2 Complex Constitutes a 3â€² Flap Endonuclease. Molecular Cell, 1999, 4, 935-947.	4.5	73
215	The RAG1 Homeodomain Recruits HMG1 and HMG2 To Facilitate Recombination Signal Sequence Binding and To Enhance the Intrinsic DNA-Bending Activity of RAG1-RAG2. Molecular and Cellular Biology, 1999, 19, 6532-6542.	1.1	112
216	Partial V(D)J Recombination Activity Leads to Omenn Syndrome. Cell, 1998, 93, 885-896.	13.5	429

#	Article	IF	Citations
217	The Effect of Me2+ Cofactors at the Initial Stages of V(D)J Recombination. Journal of Biological Chemistry, 1998, 273, 16325-16331.	1.6	38
218	The Homeodomain Region of Rag-1 Reveals the Parallel Mechanisms of Bacterial and V(D)J Recombination. Cell, 1996, 87, 263-276.	13.5	219
219	The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single Cell Resolution. SSRN Electronic Journal, 0, , .	0.4	1